Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023

Aarkstore Enterprise
Aarkstore - Lonsurf (Colorectal Cancer) - Forecast
and Market Analysis to 2023
Browse Full Report @
http://www.aarkstore.com/healthcare/87979/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-
2023
Published: Nov 2014 | No. Of Pages: 57 Pages
PDF: $ 3495| Site License : $ 6990 | Enterprise Wide License : $ 10485|
Summary
Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the
third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report
focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in
the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant,
first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of
targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments
Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the
survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain
for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive
disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not
recommended.
Taiho Pharmaceuticals Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the
treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical
announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is
preparing for regulatory submission in the US and Europe. In October 2014, Taiho announced that Lonsurf has
received FDA Fast-Track designation and had initiated rolling NDA submission. This positive outcome follows

Aarkstore Enterprise
the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent
unresectable locally advanced or metastatic CRC in Japan based on Phase II data.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT
analysis.
- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
Browse complete Report on:
http://www.aarkstore.com/healthcare/87979/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-
2023

Aarkstore Enterprise
Table of Content
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 24
5 Competitive Assessment 31
5.1 Overview 31
6 Lonsurf (TAS-102) 33
6.1 Overview 33
6.2 Efficacy 35
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37
7 Appendix 39
7.1 Bibliography 39

Aarkstore Enterprise
7.2 Abbreviations 44
7.3 Methodology 47
7.4 Forecasting Methodology 47
7.4.1 Diagnosed Colorectal Cancer Patients 47
7.4.2 Percent Drug-Treated Patients 48
7.4.3 General Pricing Assumptions 48
7.4.4 Average Body Weight and Surface Area Across the 8MM 49
7.4.5 Individual Drug Assumptions 50
7.4.6 Generic Erosion 50
7.5 Primary Research - KOLs Interviewed for this Report 51
7.6 Primary Research - Prescriber Survey 53
7.7 About the Authors 54
7.7.1 Analyst 54
7.7.2 Global Head of Healthcare 55
7.8 About GlobalData 56
7.9 Disclaimer 56
List of Tables
Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile - Lonsurf 35

Aarkstore Enterprise
Table 8: Lonsurf SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53
Related reports:
OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018
Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
North American Nerve Repair & Regeneration Market by Type (Neurostimulation, Nerve
Conduits, Nerve Protectors, Nerve Wraps, Nerve Connectors), by Procedure (Direct Nerve
Repair, Nerve Grafting, Neuromodulation Surgery, Stem Cell Therapy) -Forecast to 2019
Asian Stationary Cycle Market by Product (Recumbent Stationary Cycle, Upright Stationary
Cycle), by Pricing of Equipment ( Premium Equipment, Budget Equipment), by End User
(Vertical Markets, Health Clubs, Home Fitness) - Forecasts to 2019
Oncology Information System Market by Software (Patient Information System & TPS), &
Professional Service), Application (Medical, Radiation, & Surgical Oncology), End User
(Hospital, Government Institution, & Research Center) - Global Forecasts to 2019
Healthcare, Regulatory and Reimbursement Landscape - Norway
Arthoscopic Devices Market by Product (Arthroscopes, Arthroscopic Hand Instruments, Drill
Guide, Fluid Management Devices, Power Saver Systems, Radiofrequency Probe), by End
User (Hospitals, Orthopedic Clinics) - Global Forecast to 2019
United States Off–Label Drugs Market & Forecast
Canada Pediatric Vaccines Market, Doses, Immunization (Vaccinated), Cases & Forecast

Aarkstore Enterprise
About Aarkstore Enterprise
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We
specialize in providing online market business information on market research reports, books, magazines,
conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: +91 998 729 5242
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com